BG61729B1 - 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они - Google Patents

9-заместени-2-(2-норм-алкоксифенил)пурин-6-они Download PDF

Info

Publication number
BG61729B1
BG61729B1 BG100291A BG10029196A BG61729B1 BG 61729 B1 BG61729 B1 BG 61729B1 BG 100291 A BG100291 A BG 100291A BG 10029196 A BG10029196 A BG 10029196A BG 61729 B1 BG61729 B1 BG 61729B1
Authority
BG
Bulgaria
Prior art keywords
carbon atoms
straight
formula
group
branched
Prior art date
Application number
BG100291A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100291A (bg
Inventor
Ulrich Niewoehner
Erwin Bischoff
Helmuth Schuetz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BG100291A publication Critical patent/BG100291A/bg
Publication of BG61729B1 publication Critical patent/BG61729B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG100291A 1995-01-19 1996-01-18 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они BG61729B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (2)

Publication Number Publication Date
BG100291A BG100291A (bg) 1996-07-31
BG61729B1 true BG61729B1 (bg) 1998-04-30

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100291A BG61729B1 (bg) 1995-01-19 1996-01-18 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они

Country Status (30)

Country Link
US (1) US5866571A (es)
EP (1) EP0722943A1 (es)
JP (1) JPH08231546A (es)
KR (1) KR960029335A (es)
CN (1) CN1138583A (es)
AR (1) AR002704A1 (es)
AU (1) AU4097796A (es)
BG (1) BG61729B1 (es)
BR (1) BR9600149A (es)
CA (1) CA2167349A1 (es)
CO (1) CO4700524A1 (es)
CZ (1) CZ16896A3 (es)
DE (1) DE19501480A1 (es)
EE (1) EE9600020A (es)
FI (1) FI960226A (es)
HR (1) HRP960009A2 (es)
HU (1) HUP9600107A3 (es)
IL (1) IL116771A (es)
MA (1) MA23779A1 (es)
NO (1) NO960221L (es)
NZ (1) NZ280829A (es)
PE (1) PE10597A1 (es)
PL (1) PL312353A1 (es)
SG (1) SG47379A1 (es)
SK (1) SK7696A3 (es)
SV (1) SV1996000004A (es)
TN (1) TNSN96005A1 (es)
TR (1) TR199600701A2 (es)
YU (1) YU2896A (es)
ZA (1) ZA96399B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
CN1264843C (zh) * 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents

Also Published As

Publication number Publication date
MA23779A1 (fr) 1996-10-01
AR002704A1 (es) 1998-04-29
US5866571A (en) 1999-02-02
TNSN96005A1 (en) 2005-03-15
FI960226A (fi) 1996-07-20
YU2896A (sh) 1999-03-04
EP0722943A1 (de) 1996-07-24
JPH08231546A (ja) 1996-09-10
NO960221L (no) 1996-07-22
SG47379A1 (en) 1998-04-17
HRP960009A2 (en) 1997-12-31
CN1138583A (zh) 1996-12-25
KR960029335A (ko) 1996-08-17
CA2167349A1 (en) 1996-07-20
TR199600701A2 (tr) 1996-08-21
SK7696A3 (en) 1996-08-07
FI960226A0 (fi) 1996-01-17
CO4700524A1 (es) 1998-12-29
HUP9600107A3 (en) 1999-06-28
IL116771A (en) 1999-06-20
NO960221D0 (no) 1996-01-18
IL116771A0 (en) 1996-05-14
DE19501480A1 (de) 1996-07-25
PE10597A1 (es) 1997-06-13
NZ280829A (en) 1998-04-27
CZ16896A3 (en) 1996-08-14
EE9600020A (et) 1996-08-15
SV1996000004A (es) 1997-02-19
AU4097796A (en) 1996-07-25
HU9600107D0 (en) 1996-03-28
BR9600149A (pt) 1998-01-06
HUP9600107A2 (en) 1997-05-28
ZA96399B (en) 1996-08-14
BG100291A (bg) 1996-07-31
PL312353A1 (en) 1996-07-22

Similar Documents

Publication Publication Date Title
US11001563B2 (en) SSAO inhibitor
EP0591528B1 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
CA2237221C (en) Protein kinase c inhibitor
EP2183253B1 (en) Thieno-pyridine derivatives as mek inhibitors
RU2158733C2 (ru) Производные 2,8-дизамещенного хиназолинона или их соли, фармацевтическая композиция с воздействующей на уровень кгмп и камп активностью на их основе
US5290782A (en) Xanthine derivatives
EP1309594B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
BG61729B1 (bg) 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они
AU720305B2 (en) Purin-6-one derivatives
ES2948793T3 (es) Acidos cicloheptílicos como antagonistas de LPA
US8487101B2 (en) Thieno-pyridine derivatives as MEK inhibitors
EP3419975B1 (en) Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors
BG61728B1 (bg) 2,9-дизаместени пурин-6-они
PL205507B1 (pl) Pochodna β-karboliny i jej zastosowanie oraz kompozycja farmaceutyczna
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2021513530A (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
WO2007039580A1 (en) Imidazolyl-substituted benzophenone compounds
US5284837A (en) Derivatives of purine, process for their preparation and a pharmaceutical preparation
EP1065209B1 (fr) Nouveaux inhibiteurs de métalloprotéases, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP2011504164A (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
EP1718623B1 (en) Compounds as inhibitors of cell proliferation and viral infections
JP2006519234A (ja) 新規化合物
CN117164590A (zh) 稠合嘧啶类衍生物及其应用
WO2009037302A1 (en) 5-substituted-1, 4-benz0diazepines as phosphodiesterase inhibitors
EP0145304A1 (en) Tetrahydro-beta-carboline derivatives and process for the preparation thereof